The REFULATORY AFFAIRS Company™, part of TCTC Group™, will be attending the 29th Annual DIA Euromeeting, taking place in Glasgow, Scotland on 29th-31st of March 2017.

During the 29th DIA Euromeeting the evolving European and Global healthcare environment is going to be discussed to reflect on the outcome of recent changes such as alternative regulatory pathways; and to look ahead at emerging developments, such as how the rise of Big Data might impact medicine development, regulation, access and use. This year's moto is 'From Bench to Bedside- and Back' that reflects the growing impact of "back-translation" of learnings from the real life patient world into R&D.

The REGULATORY AFFAIRS Company™ is delighted to be participating in the event, joining leading organizations in building new connections, collaborations and partnerships. The REGULATORY AFFAIRS Company™ places great emphasis on planning clients' product road maps to suit their individual product characteristics. The company also offers the advantage of comprehensive client-side experience to companies seeking to challenge over-cautious approval strategies which are sometimes an indicator of inadequate broad spectrum Regulatory Affairs experience.

TCTC Group™ is a privately owned full-service clinical research provider specialized in bringing products with unique clinical, medical and regulatory complexities to market. In addition to offering full-service clinical trial solutions, the group includes independent divisions specialized in quality assurance, medical writing and regulatory affairs, project and site management, staffing and training services. TCTC Group™ are experts in advanced therapies and successfully executed clinical trials for the first Gene therapy to be approved in the Western world. The group also has a CNS-dedicated clinical development team conducting trials in the most complex neurological and psychiatric conditions.

The TCTC team is available to discuss your requirements and will be pleased to assist you with getting your product to market in the most cost-effective and time-efficient manner.

TCTC Group

Notes for Editors:

About The CLINICAL TRIAL Company™ group:

The Clinical Trial Company group was formed in the UK in 2002. The founders of TCTC realised there was an opportunity in the CRO sector for a company which targeted medium size clinical trials and novel products which lacked a classical road map to the market. Large CROs prioritize studies from the big pharmaceutical companies, for good business reasons. However, this approach sometimes disadvantages their smaller clients who are equally keen to complete their clinical trials quickly.

Its Directors and experienced management team offer comprehensive client-side experience to global players. This offering appeals to people unhappy with delays caused by conventional off-the-shelf approval strategies which ignore the unique nature of each product and market.

TCTC has its Group headquarters near Manchester (UK) with additional offices in Stirling (UK), San Mateo (USA), Montreal (Canada), Sydney (Australia) and Singapore. TCTC has operating divisions covering all aspects of drug development which include The CLINICAL TRIAL Company™, The REGULATORY AFFAIRS Company™, The CQA Company™, The CRA Company™, The CNS Company™ and The Clinical Training Company™.

Additional information can be found at www.tctcgroup.com

For more information contact:

Audrey Jamieson
Business Development Manager
audrey_jamieson@theclinicaltrialcompany.com
Tel: +44 (0) 1563 732 953

The CLINICAL TRIAL Company Ltd.
Mere View Barn, Park Lane
Pickmere, Knutsford
WA16 0LG, United Kingdom

TCTC Group